Advertisement
Journal Home
Search for

Volume 4, Issue 1, Pages 9-14 (March 2003)


View previous. 4 of 12 View next.

Oxygen monitoring in preterm babies: too high, too low?

Win Tin1Corresponding Author Informationemail address, Sue Walker2, Camilla Lacamp3

Abstract 

A small randomised trial in 1952 showed that excess oxygen use might well be causing a major epidemic of retinal blindness in preterm babies. That single study of just 65 babies was enough to throw doubt on a longstanding treatment strategy of oxygen therapy and highlighted just how powerful a tool the randomised controlled trial could be. Confirmatory evidence from a co-operative trial 4 years later involving 212 babies banished all residual doubt and we should reproach ourselves that we have still not learnt after 50 years how to optimise oxygen delivery to the preterm baby, making further use of this powerful research tool. Two well-conducted trials have recently shown that avoiding subclinical hypoxaemia (a fractional SaO2 of less than 92%) in babies more than a month old does nothing to improve later growth or development. It is now time the same question was asked of babies less than a month old. This is particularly important in babies of less than 28 weeks’ gestation, who currently remain at serious risk of chronic lung disease and permanent retinal damage.

Article Outline

Abstract

INTRODUCTION

HISTORICAL BACKGROUND

OXYGEN-MONITORING STRATEGIES

CONTROLLING OXYGEN SATURATION

Current variations in practice

Evidence from a recent observational study

Effect of a change in policy

Evidence from two recent randomised controlled studies

HOW MUCH OXYGEN IS APPROPRIATE IN THE FIRST MONTH OF LIFE?

Upper limit

Lower limit

THE WAY FORWARD

PRACTICE POINTS

Acknowledgment

Appendix A. 

References

Copyright

INTRODUCTION 

return to Article Outline

Oxygen is the drug most commonly used in neonatal care and is an integral part of all respiratory support. The goal of oxygen therapy is to achieve adequate oxygen delivery to the tissues without creating oxygen toxicity.

Although oxygen must have been given to more babies than has any other medicinal product over the past 60 years, we still know very little about how much babies actually need or how much it is safe to give. It is also now 50 years since the first controlled trial appeared suggesting that too much oxygen could damage the eyes of the preterm baby1 and 46 years since the first large landmark trial in neonatal medicine confirmed that although oxygen was a “good thing”, it was quite possible to have “too much of a good thing”.2

HISTORICAL BACKGROUND 

return to Article Outline

The first person to suggest in print that oxygen could be responsible for the rising epidemic of retinopathy of prematurity (or retrolental fibroplasia as it was then known) was Kate Campbell in Melbourne. She was generous enough to note that information came to her “from colleagues returning from overseas” and that the idea arose “from a comparison of the treatment of premature infants in America, where retrolental fibroplasia was a problem and where oxygen was freely used, with the treatment in England, where retrolental fibroplasia was rarely seen, and where oxygen was used sparingly”. She concluded that the “normal oxygen environment of the newborn full term infant is abnormal for the premature infant”.3 More substantial evidence came within a year from Mary Crosse in Birmingham, England4 and from a quasi-randomised trial, started in 1948, by Arnall Patz in Washington in which babies weighing less than 3.5lb were alternately assigned to care in high oxygen (65–70% for 4–7 weeks) or less than 40% oxygen for as short a time as possible (1–2 weeks) when 24hours old. Seven of the 28 babies nursed in a high oxygen concentration developed grade III–IV retinopathy, whereas none of the 37 nursed in as little oxygen as possible developed retinopathy.1

Many studies have since tried to define what constitutes a safe level of arterial oxygenation. However, the only organised attempt to build on the insight provided by the first clinical trials, published 25 years ago, used a descriptive approach and failed to provide any worthwhile additional information.5 One small study, only incompletely reported, did suggest that excess oxygen might affect the lung as well as the eye,6 but its message was largely ignored. Further collaborative trials were clearly going to be needed, but they were never carried out.7

The larger Collaborative trial, designed to replicate the Washington trial and completed in 1955,2 was widely interpreted at the time as suggesting that oxygen therapy was safe as long as the inspired oxygen concentration was not more than 40%.8 The fact that the babies in one arm of the trial had not only had more oxygen, but also had it for much longer was almost entirely overlooked. So too was the fact that some babies in the restricted exposure arm still developed eye damage. Even more seriously, it took a long time for clinicians to realise that a policy of restricting oxygen exposure rather than restricting arterial oxygen level was almost certainly causing an increase in the number of early neonatal deaths.9., 10., 11. Even in the Collaborative trial, in which restricted exposure was only started on entry into the study 48hours after birth, the mortality was 10% higher in babies allowed only a limited amount of oxygen.

OXYGEN-MONITORING STRATEGIES 

return to Article Outline

It became clear from the Collaborative trial that although excess oxygen exposure was at least one of the causes of retinopathy, there was no clarification of how oxygen administration could be optimised. Clinicians therefore started to look for ways of monitoring the arterial oxygen level. For reasons that are still hard to comprehend, the powerful tool that had so dramatically revealed at least one of the root causes of retinopathy was never employed to address the challenge of optimising oxygen use.

Indwelling arterial lines were soon being widely used to monitor arterial oxygen tension but no controlled trial has ever shown that their use reduces the risk of permanent retinal damage.12 When it first became possible to monitor oxygen tension continuously and non-invasively, one attempt was made to see whether transcutaneous monitoring could reduce the risk of excessive oxygen exposure. There was no evidence that it did,13 although a later analysis of some of the information collected during that trial suggested that retinopathy occurred more often when the transcutaneous reading reached or exceeded 80mmHg (10.7kPa) in the first 4 weeks of life.14 No comparable study seems to have been attempted since it first became commonplace, 10 years ago, to use pulse oximetry to monitor oxygen saturation.

CONTROLLING OXYGEN SATURATION 

return to Article Outline

Current variations in practice 

Babies grow perfectly well in utero with arterial blood that is only 70–80% saturated (Fig. 1).15 Why then do we persist in trying to keep their oxygen saturation after birth above 90%, even if this requires prolonged periods of supplementation or even ventilation? Children with cyanotic congenital heart disease make the transition to extra-uterine life without difficulty despite all we know about the effect that oxygen has on pulmonary vascular16 and ductal17 tone. So why do we fear that mild desaturation could dangerously compromise that transition? It is not as though there is a uniform approach to care. Views on what constitutes a safe maximum or minimum saturation for a small baby in the first few weeks of life vary widely. Figure 2 shows how practice currently varies in the UK;18 policies in America vary just as much.19


View full-size image.

Figure 1. Maternal and fetal arterial and venous oxygen saturation and partial pressure in late pregnancy.15



View full-size image.

Figure 2. Oxygen saturation monitoring policies in the UK. Results from a telephone survey of 100 units with three or more intensive care cots caring for babies of less than 28 weeks’ gestation in 2001. High (A) and low (B) oximeter alarm settings.18


Evidence from a recent observational study 

Policy has varied in the north of England over the past 10 years at least as dramatically as it has in any other part of the UK, and a prospective observational study of every baby born alive before 28 weeks’ gestation to a mother resident in the north of England in 1990–94 stated some fairly provocative findings.20 Data collection started just after the artificial surfactant colfosceril (Exosurf) became widely available in the UK as part of a major collaborative trial,21 and was linked to an epidemiological study of the long-term outcome for all babies born more than 8 weeks early.22., 23. Nasal continuous positive airway pressure (CPAP) was just coming into common use at that time but was not being employed in the initial post-delivery management of babies as immature as this. The babies were born in, or referred for care to, one of five neonatal units in which most care policies were similar, but policy towards the monitoring of oxygen saturation varied widely. The overall survival rate, and the survival rates without evidence of cerebral palsy at 18 months, was almost identical in the five units in the 295/568 babies of 23–27 weeks’ gestation (52%) still alive 1 year after birth (Table 1).20

Table 1.

Outcome at 1 year in all babies of 23–27 weeks’ gestation born in 1990–94 and its relationship to minimum and maximum pulse oximeter alarm settings.20

Oximter alarm settings (%)Number of babies admittedOne year survivors (number and percentage)
Number of survivorsMedian number of days ventilatedCerebral palsyThreshold retinopathy
88–98a12365 (52.8%)2111 (16.9%)18 (27.7%)
85–95235128 (54.5%)1620 (15.6%)20 (15.6%)
84–948437 (44.0%)156 (16.2%)5 (13.5%)
70–9012665 (51.6%)710 (15.4%)4 (6.2%)
a

Nellcor pulse oximeter measurements (functional saturation). Other measurements are fractional saturation. Target saturation lay in the upper half of the accepted range.

In one unit, the target fractional oxygen saturation (see Appendix A) was 80–90% (the lower alarm limit set to operate only if the saturation fell below 70%) once the baby was more than 2–3hours old. Such a policy was sustained for all babies thought to need supplemental oxygen until retinal vascularisation was complete. In another unit, target functional oxygen saturation was 94–98% (the lower alarm set to operate at 88%); the other three units had intermediate policies. A careful, uniform ophthalmic review of all the survivors showed that retinopathy severe enough to merit treatment with cryotherapy24 occurred in 6.2% (95% CI 1.7–15.0%) of the babies in the first of these units and 27.7% (95% CI 17.3–40.2%) in the latter (Fig. 3). No child from the first unit, but four from the latter unit, became blind. The three units employing intermediate policies for target oxygen saturation had “threshold” retinopathy rates in the middle of this range.20


View full-size image.

Figure 3. Relationship between the limits within which oxygen saturation was allowed to vary and the proportion of 1 year survivors so nursed who later developed severe (grade 3+) retinopathy of prematurity: a comparison of four policies. Staff aimed to keep saturation in the upper half of the permitted range.20 (Reproduced from ref. 20 with permission from BMJ Publishing Group.)


In the unit where the target oxygen saturation was 80–90%, half of the 65 long-term survivors were managing without respiratory support (defined as any plastic tubing below the vocal cords) by 7 days of age and without supplemental oxygen by 30 days. In the unit in which target oxygen saturation was 94–98%, these milestones were achieved by half the survivors in 21 and 72 days, respectively. Growth to discharge was curtailed twice as much in the latter unit. Eleven survivors from the first unit and 29 from the second had a weight below the third centile at discharge (possibly because nutritional intake was, quite subconsciously, increased more cautiously in babies still requiring respiratory support). Neurodevelopmental outcome was similar at 18 months (no child having been lost to follow-up).20 A further review is currently underway to establish whether there are any subtle long-term adverse consequences associated with this more “permissive” approach to mild oxygen desaturation in babies of less than 28 weeks’ gestation in the first few weeks of life.

Effect of a change in policy 

When the results of this analysis first became known, the unit that had been maintaining its functionally calibrated oximeter alarm settings at 88% and 98% modified its practice and lowered the settings to 75% and 93%. In the years 1995–96, before the change in policy, half the surviving babies of 25–27 weeks’ gestation spent more than 13 days on ventilation. In the years 1998–2000 inclusive, half the babies were weaned from ventilatory support by 5 days of age even though there had been no other change in unit policy during this time (Fig. 4).18 This within-unit change over time is comparable to the between-unit difference seen in 1990–94, strengthening the suggestion that accepting a lower target saturation may make it possible to halve the time it takes to wean babies from ventilatory support.


View full-size image.

Figure 4. Length of time that babies of 24–27 weeks’ gestation were ventilated in 1995–96 (when the upper and lower oximeter alarms were set at 98% and 88%, respectively) and in 1998–2000 (when the alarms were set at 93% and 75%).18


Evidence from two recent randomised controlled studies 

Two trials have recently been conducted to see whether it is better to keep arterial oxygen saturation high in very preterm babies when they are more than a few weeks old. The American STOP-ROP trial,25 which recruited 649 babies with a mean gestation of 25.4 weeks and a mean post-menstrual age of 35 weeks between 1994 and 1999, showed that keeping the fractional oxygen saturation above 95% slightly reduced the number of babies with pre-threshold retinopathy who went on to develop disease severe enough to require retinal surgery. Benefit was, however, seen only in those without evidence of “plus disease” (dilated and tortuous vessels in at least two quadrants of the posterior pole) at recruitment (32% vs. 46%). More unexpectedly, the higher oxygenation target significantly increased the number in hospital, in oxygen and receiving diuretics at a post-menstrual age of 50 weeks. Significant pulmonary deterioration after recruitment (13.2% vs. 8.5%) was seen only in those with more than average evidence of chronic lung disease at trial entry. The higher oxygenation target did not improve growth or the eventual retinal outcome as assessed 3 months after the expected date of delivery.

The result of the Australian BOOST trial has just been reported.26 There was no evidence that the growth and developmental outcome of babies of less than 30 weeks’ gestation at birth who were still oxygen dependent at a post-menstrual age of 32 weeks was improved by keeping their functional oxygen saturation in the high 90%s. This randomised, double-blind, multi-centre study recruited 358 babies between 1996 and 2000, and a full report of the study is likely to be published shortly. Collaborating units had different policies with regard to optimum oxygenation in the period immediately after birth (as in the STOP-ROP trial) but all monitored saturation using a pre-specified Nellcor N-3000 pulse oximeter after recruitment for as long as supplemental oxygen was deemed necessary. Trial oximeters were specially modified to keep the functional saturation in the range 91–94% or 95–98%, depending on allocation at entry, while displaying a figure in the range 93–96%.

HOW MUCH OXYGEN IS APPROPRIATE IN THE FIRST MONTH OF LIFE? 

return to Article Outline

Even if this second study had shown that it was better to keep functional saturation above 94% (approximately equivalent to a fractional saturation of 92%) in babies more than a few weeks old, this still does not address the possibility that a more permissive approach to desaturation might be preferable in the first few weeks of life. A strategy that reduces the number of babies developing retinopathy is better than one that marginally modifies the progress of neovascularisation after it has already nearly reached the point at which retinal surgery is called for.

Upper limit 

There is unfortunately no controlled trial evidence with which to shape policy. The observational study from the north of England20 suggests that the risk of retinopathy increases when the oxygen saturation is allowed to exceed approximately 90% in the first few weeks of life, a figure in line with the earlier observational study14 proposing an increase when the transcutaneous partial pressure reached or exceeded 80mmHg (since studies show that fractional oximeter readings above 92% can be associated with partial pressures of 80mmHg or more,27., 28. as Fig. 5 makes clear).


View full-size image.

Figure 5. Relationship between fractional oxygen saturation measured with a pulse oximeter and arterial partial pressure in mmHg and kPa. The dashed line marks the transcutaneous PO2 above which there was an increased risk of retinopathy in the study reported by Flynn in 1992.14 The bars in (B) show the range within which 95% of all measures of partial pressure varied when the oximeter read 90%, 92%, 94%, 96% and 98% in the study reported by Brockway and Hay in 1998.28 Note that pulse oximeters calibrated to display functional saturation produce readings about 2% higher than those reflecting fractional saturation.29., 30. (Reproduced from Neonatal Formulary 3, p. 171, Figure 1, Figure 2, 2002, with permission from BMJ Books.)


The babies in the two polar arms of the north of England study had been very similar on admission. Antenatal steroid use and the rates of death during delivery and before admission to special care were comparable. Neither adjusting for the minor difference in the distribution of gestation, nor excluding post-delivery transfers, altered any of the conclusions. Nevertheless, only a controlled trial can ever establish whether some unrecognised factor other than the difference in target oxygen saturation was responsible for the observed difference in the incidence of retinopathy, the difference in the amount of ventilatory support required and the magnitude of the post-delivery growth deficit.

Lower limit 

If there is debate over what constitutes the safe upper limit for fractional oxygen saturation, there is even greater uncertainty over what constitutes the lower safe limit. Mortality went undocumented in the first formal trial of restricted oxygen administration,1 and the second trial was large enough only to rule out a major increase.2 The current observational study,20 like the early small trial by Usher,6 is also too small to address such an issue but it does suggest that a more permissive approach to minor hypoxia may, like a permissive approach to hypercapnia, reduce the need for ventilatory support, the consequential risk of chronic lung disease and the associated health-care costs. We should not forget that the levels being discussed here are all higher than the retina and the brain would normally experience during fetal life.

THE WAY FORWARD 

return to Article Outline

The time may have come to admit that we still do not know how to optimise the delivery of supplemental oxygen to the very preterm baby and to agree to try and address this important but unanswered issue using a randomised trial, the tool best suited to addressing such an uncertainty. The main aim should be to see whether it is possible, by accepting lower saturation values, to achieve an equivalent developmental and cognitive outcome 2 and 4 years later while only ventilating babies for a much shorter period, with all the secondary short-term benefits that ought to accrue from providing less-invasive care (better early growth, less lung scarring, less infection, lower cost, etc). If it showed that fewer babies required retinal surgery, that would be a bonus.

It was collaboration across three continents that helped Campbell to identify the cause of retinopathy in the preterm baby.3 It seems likely that a similar collaboration will again be required if we are ever to optimise the use of oxygen – a product capable of doing great harm as well as great good.

PRACTICE POINTS 

return to Article Outline

Pulse oximetry is not reliable in detecting hyperoxia if oxygen saturation is kept above 92%.

Oxygen toxicity is not confined to retinopathy: consider, for example, pulmonary oxygen toxicity in vulnerable preterm babies.

There is still a wide variation in oxygen saturation monitoring policies between neonatal intensive care units.

Attempts to keep the oxygen saturation at a so-called “physiological” level for healthy term or adults may do more harm than good in very preterm babies.

Acknowledgements 

return to Article Outline

We are very grateful to Edmund Hey for help in the preparation of this paper.

Appendix A. 

return to Article Outline

References 

return to Article Outline

1.. 1. Patz A, Hoeck LE, de la Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. 1. Nursery observations. Am. J. Ophthalmol. 1952;35:1248–1253. MEDLINE

2.. 2. Kinsey VE, Jacobus JT, Hemphill F. Retrolental fibroplasia: cooperative study of retrolental fibroplasia and the use of oxygen. Arch. Ophthalmol. 1956;56:481–543.

3.. 3. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med. J. Austr. 1951;ii:48–50.

4.. 4. Crosse VM, Evans PJ. Prevention of retrolental fibroplasia. Arch. Ophthalmol. 1952;48:83–87.

5.. 5. Kinsey VE, Arnold HJ, Kalina RE, et al.  PaO2 levels and retrolental fibroplasia. Pediatrics. 1977;60:655–668.

6.. 6. Usher R. Treatment of respiratory distress. In: Winters RW (ed.) Body Fluids in Pediatrics. Boston: Little, Brown, 1973; 303–337.

7.. 7. Les Chermignonards Désenchantés. Oxygen and retrolental fibroplasia. Pediatrics 1977; 60: 753–754; see also 1978; 62: 439–440.

8.. 8. Guy LP, Lanman TJ, Dancis J. The possibility of total elimination of retrolental fibroplasia by oxygen restriction. Pediatrics. 1956;17:247–249.

9.. 9. Avery ME, Oppenheimer EH. Recent increase in mortality in hyaline membrane disease. J. Pediatr. 1960;57:553–559. Abstract | Full-Text PDF (439 KB) | CrossRef

10.. 10. Cross KW. Cost of preventing retrolental fibroplasia?. Lancet. 1973;ii:954–956.

11.. 11. Bolton DPG, Cross KW. Further observations on the cost of preventing retrolental fibroplasia. Lancet. 1974;i:445–448.

12.. 12. Duc G, Sinclair JC. Oxygen administration. In: Sinclair JC, Bracken MB (eds.) Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992; 178–199.

13.. 13. Flynn JT, Bancalari E, Bawol R, et al.  Retinopathy of prematurity. A randomized prospective trial of transcutaneous oxygen monitoring. Ophthalmology. 1987;94:630–638. Abstract

14.. 14. Flynn JT, Bancalari E, Snyder ES et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326: 1050–1054; see also 1078–1080.

15.. 15. Nicolini U, Nicolaidis P, Fisk NM, et al.  Limited role of fetal blood sampling in prediction of outcome in intrauterine growth retardation. Lancet. 1990;336:768–772. Abstract | CrossRef

16.. 16. Dawes GS. Pulmonary circulation in the foetus and new-born. Br. Med. Bull. 1966;22:61–65. MEDLINE

17.. 17. Skinner JR, Hunter S, Poets CF, et al.  Haemodynamic effects of altering arterial oxygen saturation in preterm infants with respiratory failure. Arch. Dis. Child. 1999;80:F81–F87.

18.. 18. Lacamp C, Walker S. Oxygen monitoring: too low or too high. National survey of oxygen saturation monitoring policies and the audit on the effect of change of policy in a single neonatal intensive unit. Early Hum Dev 2002 (Abstract, in press).

19.. 19. Vijayakumar E, Ward GJ, Bullock CE, et al.  Pulse oximetry in infants <1500 gm at birth on supplemental oxygen: a national survey. J. Perinatol. 1997;17:341–345. MEDLINE

20.. 20. Tin W, Milligan DWA, Pennefather P et al. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child 2001; 84: F106–F110; see also F75–F76, F149–F150.

21.. 21. OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant – the judgement of OSIRIS. Lancet 1992; 340: 1363–1369.

22.. 22. Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Lancet 1996; 348: 229–232.

23.. 23. Tin W, Fritz S, Wariyar U, et al.  Outcome of very preterm birth: children reviewed with ease at 2 years differ from those followed up with difficulty. Arch. Dis. Child. 1998;79:F83–F87.

24.. 24. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicentre trial of cryotherapy for retinopathy of prematurity: one-year outcome – structure and function. Arch Ophthalmol 1990; 108: 1408–1416.

25.. 25. The STOP-ROP Multicentre Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomised, controlled trial. Pediatrics 2000; 105: 295–319.

26.. 26. Askie L, Henderson-Smark D, Irwig L, et al.  The effect of differing oxygen saturation targeting ranges on long term growth and development of extremely preterm, oxygen dependent infants: the BOOST trial. Pediatr. Res. 2002;51:378A.

27.. 27. Hay WW, Brockway JM, Eyzaquirre M. Neonatal pulse oximetry: accuracy and reliability. Pediatrics. 1989;83:717–722.

28.. 28. Brockway J, Hay WW. Prediction of arterial partial pressure of oxygen with pulse oxygen saturation measurements. J. Pediatr. 1998;133:63–66. Abstract | Full Text | Full-Text PDF (154 KB) | CrossRef

29.. 29. Thilo EH, Anderson D, Wasserstein ML, et al.  Saturation by pulse oximetry: comparison of the results obtained by instruments of different brands. J. Pediatr. 1993;122:620–626. Abstract | Full-Text PDF (512 KB) | CrossRef

30.. 30. Moyle JTB. Pulse Oximetry. London: BMJ Books, 1994.

1 Consultant Paediatrician and Neonatologist, Department of Paediatrics and Neonatal Medicine, The James Cook University Hospital, Middlesbrough, UK

2 Advanced Neonatal Nurse Practitioner, Department of Paediatrics and Neonatal Medicine, The James Cook University Hospital, Middlesbrough, UK

3 Clinical Fellow in Paediatrics and Neonatology, Department of Paediatrics and Neonatal Medicine, The James Cook University Hospital, Middlesbrough, UK

Corresponding Author InformationCorrespondence to: Win Tin. Tel.: +44-1642-854834; Fax: +44-1642-854830

PII: S1526-0542(02)00307-X

doi:10.1016/S1526-0542(02)00307-X


View previous. 4 of 12 View next.